WORCESTER, Mass.--(BUSINESS WIRE)--RXi Pharmaceuticals Corporation (Nasdaq: RXII), a leading company in RNA targeting, today announced that RXi scientists will present new data on the mechanism of RNAi compounds in cells at the premier academic RNAi meeting, Keystone Symposia’s RNAi, MicroRNA, and Non-coding RNA, March 25-30, 2008. The experimental results of RXi’s research indicate that RXi’s proprietary rxRNA™ compounds are not cleaved by the dicer enzyme and that dicer processing is not required for the generation of extremely potent RNAi compounds.
